World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
45217
World Ranking
10680
National Ranking
5491

Overview

Marc S. Ernstoff is affiliated with the Roswell Park Cancer Institute in the United States. Their work primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a strong focus on Oncology, Molecular Biology, Immunology, Genetics, and Pulmonary and Respiratory Medicine.

The scientific contributions of Marc S. Ernstoff emphasize cancer-related immunotherapy and molecular research. Their main areas of study include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T Cell Therapy Research
  • Cutaneous Melanoma Detection and Management
  • Cancer Genomics and Diagnostics
  • Melanoma and MAPK Pathways
  • Brain Metastases and Treatment

Marc S. Ernstoff has published frequently in the following venues:

  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • Regular and Young Investigator Award Abstracts
  • Annals of Oncology
  • Journal of Translational Medicine

Notable recent papers include:

  • "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events," 2021, Journal for ImmunoTherapy of Cancer
  • "NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020," 2020, Journal of the National Comprehensive Cancer Network
  • "COVID-19 and Cancer: a Comprehensive Review," 2020, Current Oncology Reports
  • "Systemic Therapy for Melanoma: ASCO Guideline," 2020, Journal of Clinical Oncology
  • "Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy," 2020, Annals of Oncology

Collaborations are a significant component of their research, frequently working with the following co-authors:

  • Igor Puzanov
  • Pauline Funchain
  • Irene Orlow
  • Eva Hernando
  • Nancy E. Thomas

Best Publications

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

    John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith

  • Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

    I. Puzanov;A. Diab;K. Abdallah;C. O. Bingham

  • High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

    John M. Kirkwood;Joseph G. Ibrahim;Jeffrey A. Sosman;Vernon K. Sondak

  • Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

    Hussein A. Tawbi;Peter A. Forsyth;Alain Algazi;Omid Hamid

  • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial

    Kim Margolin;Marc S Ernstoff;Omid Hamid;Donald Lawrence

  • High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

    John M. Kirkwood;Joseph G. Ibrahim;Vernon K. Sondak;Jon Richards

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

    David F. McDermott;Meredith M. Regan;Joseph I. Clark;Lawrence E. Flaherty

  • Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

    Paul B. Chapman;Lawrence H. Einhorn;Michael L. Meyers;Scott Saxman

  • Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes

    Paulo C. Rodriguez;Marc S. Ernstoff;Claudia Hernandez;Michael Atkins

  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    F. Stephen Hodi;Christopher L. Corless;Anita Giobbie-Hurder;Jonathan A. Fletcher

  • A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

    John M. Kirkwood;Judith Manola;Joseph Ibrahim;Vernon Sondak

  • Management of Immunotherapy-Related Toxicities, Version 1.2019.

    John A. Thompson;Bryan J. Schneider;Julie Brahmer;Stephanie Andrews

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

    Bryan J Schneider;Jarushka Naidoo;Bianca D Santomasso;Christina Lacchetti

  • Society for immunotherapy of cancer (sitc) clinical practice guideline on immune checkpoint inhibitor-related adverse events

    Julie R. Brahmer;Hamzah Abu-Sbeih;Paolo Antonio Ascierto;Jill Brufsky

  • VISTA Is an Immune Checkpoint Molecule for Human T Cells

    Janet Lines;Eirini Pantazi;Justin Mak;Lorenzo F Sempere

  • Homozygous deletions within human chromosome band 9p21 in melanoma.

    J W Fountain;M Karayiorgou;M S Ernstoff;J M Kirkwood

  • Interferons in the treatment of human cancer.

    J M Kirkwood;M S Ernstoff

Frequent Co-Authors

John M. Kirkwood
John M. Kirkwood University of Pittsburgh
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Igor Puzanov
Igor Puzanov Roswell Park Cancer Institute
Michael B. Atkins
Michael B. Atkins Georgetown University
Kim Margolin
Kim Margolin City Of Hope National Medical Center
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Paul K. Wallace
Paul K. Wallace Roswell Park Cancer Institute
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
James H. Finke
James H. Finke Cleveland Clinic Lerner College of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine isn’t the only pathway to a fulfilling healthcare career in the USA. A range of online degrees can expand your options, offering flexible routes into fast-growing professions. For instance, pursuing a nutritionist online degree is ideal for those interested in promoting public health and wellness through diet and nutritional science.

Interested in healthcare leadership? Enrolling in online mha programs prepares graduates for management roles in hospitals, clinics, or health agencies. For working nurses who want career advancement without on-campus commitments, rn to bsn programs without clinicals save time while building essential skills.

If you aspire to the highest clinical or academic nursing roles, the shortest online dnp program options offer advanced doctoral training in a streamlined format.

Each online pathway has unique admissions and licensure requirements, so it’s important to research them carefully before choosing your direction in healthcare.

Best Scientists Citing Marc S. Ernstoff

Trending Scientists